UBS Maintains a 'Buy' on Par Pharmaceutical (PRX); Strong Generics Sales; Brands Disappoint
Tweet Send to a Friend
UBS maintains a 'Buy' on Par Pharmaceutical (NYSE: PRX), raises PT by $1 to $40.
UBS analyst says, "What we ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
UBS analyst says, "What we ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
